Medicines Discovery Catapult is inviting UK SMEs working in medicines development to work together on high-resolution analysis of potential drug targets.
The centre, which was established to support innovative drug discovery across the nation, is offering access to an atomic resolution Solid State NMR (SSNMR) at its facility within the University of Warwick, along with world-leading scientific support, including data analysis and interpretation.
The aim is to provide SMEs with atomic resolution of a compound, protein structure or complex and its dynamic interactions, which are not normally amenable to resolution by other approaches.
“We’re looking for innovative, dynamic partners with technically feasible proposals that will bring about significant new advances. This is an excellent opportunity for a UK SME to accelerate their R&D,” noted Dr Peter Simpson, chief scientific officer of Medicines Discovery Catapult.
We look forward to hearing from interested parties who wish to translate research into new solutions for improved patient health using Atomic Resolution SSNMR for structure determination in medicine discovery or development.”
The Catapult is inviting UK-registered micro, small or medium-sized enterprises engaged in drug discovery and drug re-purposing to apply by the end of November.
